Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development

Cambridge, UK, 24 April 2025: CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix^® technologyacross existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development.

The initial phase of the collaboration will focus on validating CN Bio’s PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies.

Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron’s facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges.

Dr Paul Brooks, CEO, CN Bio, said: “Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before.

Dr Tomasz Kostrzewski, CSO, CN Bio, commented: “The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.”

Dr Hua Yang, CSO, Pharmaron, added: “We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners’ development programs.”

ENDS

About CN Bio cn-bio.com

CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated.

CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable effective therapeutics to be developed safely. Throughout the discovery and development process, the Company’s portfolio of products and services help save time and reduce costs.

Based in Cambridge (UK), CN Bio brings over a decade of experience and know-how to engineering single and multi-organ microphysiological systems (MPS). As a result, the Company’s ground-breaking benchtop PhysioMimix^® OOC range can accurately mimic human physiology in the laboratory. Using advanced, predictive in vitro human organ models, these systems enable the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models also offer valuable insights into how drugs will perform in patients, greatly reducing risks in the clinic.

The power of PhysioMimix^® technology has been recognized by the US FDA, resulting in the first co- publication between a drug regulator and an MPS provider and has been harnessed by 13 of the leading pharmaceutical companies. In 2023, the Company supported Inipharm’s INI-822 for metabolic liver disease treatment, now in clinical testing.

To find out more about CN Bio and how the Company is pioneering faster, more accurate drug discovery, please visit: cn-bio.com

Follow CN Bio on LinkedIn @CN Bio and X @CN_Bio.

About Pharmaron www.pharmaron.com

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and new modalities, including peptides, oligos, protein degraders, vaccines, cell & gene therapy products. With over 21,000 employees, and major operations in China, UK and US, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners globally.